GHRP-2vsHCG

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide that binds to the GHS-R1a receptor on pituitary somatotrophs with high affinity, making it the second most potent GHRP for GH release after hexarelin. It activates the canonical Gq/11-PLC-IP3-calcium pathway, triggering robust GH vesicle exocytosis.

Beyond direct pituitary action, GHRP-2 modulates GH release at the hypothalamic level through two complementary mechanisms. It stimulates GHRH-producing neurons in the arcuate nucleus, amplifying the endogenous GHRH signal, and simultaneously suppresses somatostatin release from periventricular neurons, removing the inhibitory brake on GH secretion. This dual hypothalamic action explains why combining GHRP-2 with a GHRH analogue produces synergistic rather than merely additive GH release — the GHRP removes somatostatin inhibition while the GHRH analogue directly activates somatotrophs.

GHRP-2 occupies a middle ground in the GHRP family regarding selectivity. It produces moderate cortisol and prolactin elevation — less than hexarelin but more than ipamorelin. Its ghrelin-mimetic activity also stimulates appetite through hypothalamic NPY/AgRP neurons, though this effect is less pronounced than GHRP-6. Some research suggests GHRP-2 may have gastroprotective properties, with studies showing protection against ethanol-induced gastric mucosal damage in animal models. The peptide has been most extensively studied in Japan, where clinical trials evaluated its potential for treating GH deficiency, and it remains one of the best-characterized GHRPs in terms of pharmacology and dose-response relationships.

Human Chorionic Gonadotropin is a glycoprotein hormone composed of two non-covalently linked subunits: an alpha subunit (92 amino acids, shared with LH, FSH, and TSH) and a unique beta subunit (145 amino acids) that confers biological specificity. HCG's beta subunit shares approximately 85% amino acid homology with the LH beta subunit, allowing HCG to bind and activate the LH/CG receptor (LHCGR) on Leydig cells in the testes with equal or greater affinity than LH itself.

LHCGR is a Gs-coupled GPCR that activates adenylyl cyclase upon ligand binding, increasing intracellular cAMP. cAMP activates PKA, which phosphorylates the steroidogenic acute regulatory protein (StAR). Phosphorylated StAR transports cholesterol from the outer to the inner mitochondrial membrane — the rate-limiting step in steroid hormone synthesis. Inside the mitochondria, the cholesterol side-chain cleavage enzyme (CYP11A1) converts cholesterol to pregnenolone, which then undergoes a series of enzymatic conversions (through the delta-4 or delta-5 pathway) to produce testosterone. This entire steroidogenic cascade occurs within Leydig cells and produces intratesticular testosterone concentrations 50-100 times higher than serum levels — essential for spermatogenesis in the adjacent seminiferous tubules.

HCG's longer half-life compared to LH (24-36 hours vs 20 minutes) is due to its heavily glycosylated beta subunit, which reduces renal clearance. This extended duration makes it practical for intermittent injection protocols. In addition to stimulating testosterone, HCG activates aromatase (CYP19A1) in Leydig cells, converting some of the produced testosterone to estradiol — which is why HCG use can elevate estrogen levels, potentially causing gynecomastia and water retention. HCG also maintains Sertoli cell function (which supports spermatogenesis) through indirect paracrine signaling from testosterone-producing Leydig cells. The physical preservation of testicular volume during TRT is a direct result of maintained Leydig cell activity and seminiferous tubule function.